Literature DB >> 23355190

Unveiling the binding mode of adenosine deaminase inhibitors to the active site of the enzyme: implication for rational drug design : presented by Maria P. Abbracchio.

Maria Letizia Trincavelli1.   

Abstract

Mesh：

Substances：

Year:  2013        PMID： 23355190      PMCID： PMC3568426          DOI： 10.1007/s11302-013-9353-8

Source DB:  PubMed          Journal:  Purinergic Signal        ISSN： 1573-9538            Impact factor:   3.765


× No keyword cloud information.
  16 in total

1.  Sampling protein motion and solvent effect during ligand binding.

Authors:  Vittorio Limongelli; Luciana Marinelli; Sandro Cosconati; Concettina La Motta; Stefania Sartini; Laura Mugnaini; Federico Da Settimo; Ettore Novellino; Michele Parrinello
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-11       Impact factor: 11.205

2.  Exploring complex protein-ligand recognition mechanisms with coarse metadynamics.

Authors:  Matteo Masetti; Andrea Cavalli; Maurizio Recanatini; Francesco Luigi Gervasio
Journal:  J Phys Chem B       Date:  2009-04-09       Impact factor: 2.991

Review 3.  SCID: the role of adenosine deaminase deficiency.

Authors:  R Resta; L F Thompson
Journal:  Immunol Today       Date:  1997-08

4.  Tight-binding inhibitors--IV. Inhibition of adenosine deaminases by various inhibitors.

Authors:  R P Agarwal; T Spector; R E Parks
Journal:  Biochem Pharmacol       Date:  1977-03-01       Impact factor: 5.858

Review 5.  Adenosine and related drugs in brain diseases: present and future in clinical trials.

Authors:  Luísa V Lopes; Ana M Sebastião; Joaquim A Ribeiro
Journal:  Curr Top Med Chem       Date:  2011       Impact factor: 3.295

6.  The blockade of adenosine deaminase ameliorates chronic experimental colitis through the recruitment of adenosine A2A and A3 receptors.

Authors:  Luca Antonioli; Matteo Fornai; Rocchina Colucci; Oriana Awwad; Narcisa Ghisu; Marco Tuccori; Federico Da Settimo; Concettina La Motta; Gianfranco Natale; Emiliano Duranti; Agostino Virdis; Corrado Blandizzi
Journal:  J Pharmacol Exp Ther       Date:  2010-07-28       Impact factor: 4.030

7.  Rational design of non-nucleoside, potent, and orally bioavailable adenosine deaminase inhibitors: predicting enzyme conformational change and metabolism.

Authors:  Tadashi Terasaka; Kiyoshi Tsuji; Takeshi Kato; Isao Nakanishi; Takayoshi Kinoshita; Yasuko Kato; Masako Kuno; Takeshi Inoue; Kohichiro Tanaka; Katsuya Nakamura
Journal:  J Med Chem       Date:  2005-07-28       Impact factor: 7.446

8.  Novel, highly potent adenosine deaminase inhibitors containing the pyrazolo[3,4-d]pyrimidine ring system. Synthesis, structure-activity relationships, and molecular modeling studies.

Authors:  Federico Da Settimo; Giampaolo Primofiore; Concettina La Motta; Sabrina Taliani; Francesca Simorini; Anna Maria Marini; Laura Mugnaini; Antonio Lavecchia; Ettore Novellino; Daniela Tuscano; Claudia Martini
Journal:  J Med Chem       Date:  2005-08-11       Impact factor: 7.446

9.  Inhibition of adenosine deaminase attenuates inflammation in experimental colitis.

Authors:  Luca Antonioli; Matteo Fornai; Rocchina Colucci; Narcisa Ghisu; Federico Da Settimo; Gianfranco Natale; Olga Kastsiuchenka; Emiliano Duranti; Agostino Virdis; Cristina Vassalle; Concettina La Motta; Laura Mugnaini; Maria Cristina Breschi; Corrado Blandizzi; Mario Del Taca
Journal:  J Pharmacol Exp Ther       Date:  2007-05-08       Impact factor: 4.030

10.  Exploiting the pyrazolo[3,4-d]pyrimidin-4-one ring system as a useful template to obtain potent adenosine deaminase inhibitors.

Authors:  Concettina La Motta; Stefania Sartini; Laura Mugnaini; Silvia Salerno; Francesca Simorini; Sabrina Taliani; Anna Maria Marini; Federico Da Settimo; Antonio Lavecchia; Ettore Novellino; Luca Antonioli; Matteo Fornai; Corrado Blandizzi; Mario Del Tacca
Journal:  J Med Chem       Date:  2009-03-26       Impact factor: 7.446
View more
  1 in total

1.  Possible Role of Adenosine in COVID-19 Pathogenesis and Therapeutic Opportunities.

Authors:  Jonathan D Geiger; Nabab Khan; Madhuvika Murugan; Detlev Boison
Journal:  Front Pharmacol       Date:  2020-11-26       Impact factor: 5.810
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.